| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | 0.072 | 0.6 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.03 | 0.6 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.031 | 0.6 |